167 related articles for article (PubMed ID: 23982883)
21. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
22. Multiple roles of ERCC1-XPF in mammalian interstrand crosslink repair.
Rahn JJ; Adair GM; Nairn RS
Environ Mol Mutagen; 2010 Jul; 51(6):567-81. PubMed ID: 20658648
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
[TBL] [Abstract][Full Text] [Related]
24. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin.
Mohammed MQ; Retsas S
Anticancer Drugs; 2000 Nov; 11(10):859-63. PubMed ID: 11142694
[TBL] [Abstract][Full Text] [Related]
26. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
van Huis-Tanja LH; Kweekel DM; Lu X; Franken K; Koopman M; Gelderblom H; Antonini NF; Punt CJ; Guchelaar HJ; van der Straaten T
Mutat Res; 2014 Jan; 759():37-44. PubMed ID: 24220697
[TBL] [Abstract][Full Text] [Related]
27. The knock-down of ERCC1 but not of XPF causes multinucleation.
Rageul J; Frëmin C; Ezan F; Baffet G; Langouët S
DNA Repair (Amst); 2011 Sep; 10(9):978-90. PubMed ID: 21839691
[TBL] [Abstract][Full Text] [Related]
28. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.
Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M
BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898
[TBL] [Abstract][Full Text] [Related]
29. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
[TBL] [Abstract][Full Text] [Related]
31. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
32. ERCC1-XPF endonuclease facilitates DNA double-strand break repair.
Ahmad A; Robinson AR; Duensing A; van Drunen E; Beverloo HB; Weisberg DB; Hasty P; Hoeijmakers JH; Niedernhofer LJ
Mol Cell Biol; 2008 Aug; 28(16):5082-92. PubMed ID: 18541667
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
[TBL] [Abstract][Full Text] [Related]
34. Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.
Ahmad A; Enzlin JH; Bhagwat NR; Wijgers N; Raams A; Appledoorn E; Theil AF; J Hoeijmakers JH; Vermeulen W; J Jaspers NG; Schärer OD; Niedernhofer LJ
PLoS Genet; 2010 Mar; 6(3):e1000871. PubMed ID: 20221251
[TBL] [Abstract][Full Text] [Related]
35. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
37. The Fanconi anemia protein, FANCG, binds to the ERCC1-XPF endonuclease via its tetratricopeptide repeats and the central domain of ERCC1.
Wang C; Lambert MW
Biochemistry; 2010 Jul; 49(26):5560-9. PubMed ID: 20518486
[TBL] [Abstract][Full Text] [Related]
38. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
39. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
Bergstralh DT; Sekelsky J
Trends Genet; 2008 Feb; 24(2):70-6. PubMed ID: 18192062
[TBL] [Abstract][Full Text] [Related]
40. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
